Insider Selling: Natera (NASDAQ:NTRA) CEO Sells 1,698 Shares of Stock

Key Points

• Natera CEO Steven Chapman sold 1,698 shares for approximately $545,041 at an average price of $320.99 under a pre-arranged Rule 10b5-1 trading plan, reducing his holdings by 1.7% to 98,199 shares.
• Natera shares recently traded at $327.67, near their 12-month high of $343.18. The company’s latest quarterly revenue rose 37.7% year over year to $752.75 million, while its adjusted loss of $0.47 per share was slightly better than estimates.
• Analysts maintain a generally positive view, with a consensus “Moderate Buy” rating and an average price target of $319.38; institutional investors own 99.9% of the stock.

Natera, Inc. (NASDAQ:NTRA - Get Free Report) CEO Steven Chapman sold 1,698 shares of the company's stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $320.99, for a total transaction of $545,041.02. Following the transaction, the chief executive officer owned 98,199 shares in the company, valued at $31,520,897.01. This represents a 1.70% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Steven Leonard Chapman also recently made the following trade(s):

• On Monday, August 3rd, Steven Chapman sold 3,076 shares of Natera stock. The stock was sold at an average price of $266.39, for a total transaction of $819,415.64.
• On Tuesday, July 28th, Steven Chapman sold 3,580 shares of Natera stock. The shares were sold at an average price of $254.07, for a total transaction of $909,570.60.
• On Monday, July 27th, Steven Chapman sold 2,190 shares of Natera stock. The shares were sold at an average price of $260.49, for a total transaction of $570,473.10.

Natera Trading Up 0.8%

NTRA stock traded up $2.50 on Thursday, hitting $327.67. The company had a trading volume of 708,176 shares, compared to its average volume of 1,439,570. Natera, Inc. has a 12-month low of $157.43 and a 12-month high of $343.18. The stock's 50-day simple moving average is $291.29 and its 200 day simple moving average is $237.00. The stock has a market cap of $47.23 billion, a price-to-earnings ratio of -240.93 and a beta of 1.54.

Natera (NASDAQ:NTRA - Get Free Report) last posted its earnings results on Thursday, August 6th. The medical research company reported ($0.47) EPS for the quarter, topping analysts' consensus estimates of ($0.49) by $0.02. The business had revenue of $752.75 million during the quarter, compared to the consensus estimate of $661.24 million. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The firm's revenue was up 37.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.74) EPS. Research analysts forecast that Natera, Inc. will post -1.02 earnings per share for the current year.

Hedge Funds Weigh In On Natera

Institutional investors have recently bought and sold shares of the stock. Trust Co. of Vermont purchased a new position in Natera during the second quarter valued at $26,000. Reflection Asset Management bought a new stake in Natera during the fourth quarter valued at about $29,000. Elevation Wealth Partners LLC purchased a new stake in Natera in the second quarter worth about $30,000. Palladiem LLC purchased a new stake in Natera in the fourth quarter worth about $31,000. Finally, Horizon Investments LLC bought a new position in shares of Natera in the third quarter worth about $32,000. 99.90% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. BTIG Research upped their price objective on Natera from $290.00 to $320.00 and gave the company a "buy" rating in a research report on Friday, August 7th. Royal Bank Of Canada boosted their price target on Natera from $275.00 to $350.00 and gave the company an "outperform" rating in a research note on Friday, August 7th. Sanford C. Bernstein initiated coverage on shares of Natera in a research report on Friday, June 26th. They set an "outperform" rating and a $310.00 price target for the company. Canaccord Genuity Group set a $375.00 price objective on shares of Natera in a research note on Friday, August 7th. Finally, Robert W. Baird set a $348.00 price objective on shares of Natera in a report on Friday, August 7th. Two analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $319.38.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source